Cartesian Therapeutics RNAC
NASDAQ RNAC
$7.36 +0.14 (+1.94%)
At close: Oct 2, 2026 · 4:00 PM EDT

Cartesian Therapeutics (RNAC) Other Accumulated Expenses (2015 - 2016)

Updated

Cartesian Therapeutics (RNAC) reported Other Accumulated Expenses of $831,000 for Q2 2016.

Analysis

Cartesian Therapeutics (RNAC) Other Accumulated Expenses (2015 - 2016) Analysis & Trends

At the end of FY2015, Cartesian Therapeutics posted Other Accumulated Expenses of $223,000.

Peer Set

Peer Comparison

# Company Market Cap Enterprise Value Gross Profit (Qtr)
1 Eli Lilly 1,076.25 Bn 1,044.84 Bn 19.71 Bn
2 Johnson & Johnson 617.18 Bn 535.70 Bn 17.26 Bn
3 AbbVie 464.58 Bn 437.73 Bn 12.70 Bn
4 Merck 356.04 Bn 310.47 Bn 12.21 Bn
5 Novartis Ag 269.07 Bn 224.94 Bn 11.24 Bn
6 Astrazeneca 243.21 Bn 216.77 Bn 12.86 Bn
7 Amgen 217.88 Bn 173.28 Bn 7.24 Bn
8 Gilead Sciences 179.62 Bn 153.74 Bn 6.22 Bn
9 Pfizer 158.45 Bn 105.40 Bn 10.94 Bn
10 Cartesian Therapeutics 221.08 Mn 221.08 Mn -
Historic Data

Historic Data

Download Data
DateValue
Jun 30, 2016 831,000.00
Dec 31, 2015 223,000.00
API Access

Cartesian Therapeutics Other Accumulated Expenses API

Pull this series into your own models, spreadsheets and apps with the Business Quant Historical Metrics API. The request below matches the chart above — change the frequency, period or values and it follows. Swap YOUR_API_KEY for your own key.

https://data.businessquant.com/historic?slug=other-accumulated-expenses&ticker=RNAC&period=max&api_key=YOUR_API_KEY